All In Biotech

Drug Trial Radar · NCT05607641

Efficacy and Safety Study of Ketorolac / Pitofenone / Fenpiverinium for the Treatment of Patients With Pain After Surgical Abdominal and Pelvic Operations

A Multicenter, Randomized, Open-Label, Phase II/III Clinical Trial Evaluating the Efficacy and Safety of a Fixed Combination of Ketorolac / Pitofenone / Fenpiverinium Compared to Active Control in Patients With Pain After Surgical Abdominal and Pelvic Operations

Last checked: Nov 20, 2026Latest source record: Nov 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 424 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

424

Actual

Start

Jul 7, 2021

Primary completion

May 7, 2022

Study completion May 13, 2022

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neospastil (ketorolac tromethamine / pitofenone hydrochloride / fenpiverinium bromide fixed-dose combination) in a form of solution for injections and film-coated tablets has been studied as a treatment for pain after surgical abdominal and pelvic operations. The aim of the study was to test the hypothesis that Neospastil was non-inferior (phase II) and superior (phase III) than ketorolac tromethamine monotherapy due to the additional relaxing effect of pitofenone and fenpiverinium on the smooth muscles of internal organs. The study also aimed to show that Neospastil is safe and well-tolerated in people who have pain after surgical abdominal and pelvic operations. Study treatment was initiated with parenteral form of study drug (first 24 hours) and then switched to oral formulation. This trial was conducted in accordance with the ethical principles of Good Clinical Practice and International Council for Harmonization (ICH) Harmonized Tripartite Guidelines.

Conditions

  • Postsurgical Pain

Interventions

  • Ketorolac tromethamine, solution for injection then Neospastil, film-coated tabletsDrug

    These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III). Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours. Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.

  • Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tabletsDrug

    These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III). Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours. Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.

  • Neospastil, solution for injection then Neospastil, film-coated tabletsDrug

    These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III). Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours. Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of study subjects who achieved a response to treatment within the first 24 hours of using IMP in the form of solution for injections.Time frame: Stage 1 (1st day of treatment).
  2. Proportion of study subjects who achieved a response to treatment within the first 24 hours of using IMP in the form of tablets.Time frame: Stage 2 (2nd day of treatment).

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Regional municipal nonprofitable institution "Chernivtsi regional clinical hospital", urological department

    Chernivtsi, Ukraine

  • Communal enterprise "Dnipropetrovsk Regional Clinical Hospital named after І.І. Mechnikov" Dnipropetrovsk Regional Council", urology department №1

    Dnipro, Ukraine

  • Communal enterprise "Dnipropetrovsk Regional Clinical Hospital named after І.І. Mechnikov" Dnipropetrovsk Regional Council", urology department №2

    Dnipro, Ukraine

  • Communal noncomercial enterprise of the Kharkiv Regional Council "Regional Medical Clinical Center of Urology and Nephrology named after V.I. Shapovala", urology department №5

    Kharkiv, Ukraine

  • Communal noncomercial enterprise "Kyiv City Clinical Hospital #3" Kyiv City Council (Kyiv City State Administration), urological department

    Kyiv, Ukraine

  • Medical Center of the LLC "Harmony of Beauty"

    Kyiv, Ukraine

  • State Institution "Institute of Urology of the National Academy of Medical Sciences of Ukraine", I Urological Department

    Kyiv, Ukraine

  • Communal noncomercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Hospital", department of urology

    Lviv, Ukraine

  • Municipal Non-profit Enterprise "Lviv Clinical Hospital for Emergency Medical Care"

    Lviv, Ukraine

  • Communal noncomercial enterprise "City Clinical Hospital #10" Odesa City Council, urological department #2

    Odesa, Ukraine

  • Medical-diagnostic center" Zakarpattya center of surgical innovations" Astra-med "of limited liability company" Clinic of healthy family "Astramed"

    Uzhhorod, Ukraine

  • Communal noncomercial enterprise" Vinnytsia City Clinical Hospital" Mother and Child Center", department of gynecology with minimally invasive operations

    Vinnytsia, Ukraine

  • Limited Liability Company "Innomed Center of Endosurgery"

    Vinnytsia, Ukraine

  • Communal noncomercial enterprise "City Hospital of Emergency and Ambulance" of Zaporizhia City Council, Department of Surgery with the Center for Gastrointestinal Bleeding

    Zaporizhzhya, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.